This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

183 results

Sitemap

GlaxoSmithKline (GSK) UK healthcare professional website site map.

HIV

HIV

Terms of Use

GSK UK healthcare professional website terms of use

HIV

Welcome to the HIV therapy area, for information and resources on dolutegravir and our HIV medicines (TRIUMEQ and TIVICAY).

ERS 2017

ERS European Respiratory Society 2016 Congress Report, summary of sessions by GSK’s global medical experts in asthma and COPD, expert quotes and highlights on new respiratory data and opinion

Congress Highlights

Read about some of the key asthma and COPD sessions, captured through the eyes of GSK’s Global Medical Experts.

ATS 2017

ATS American Thoracic Society 2016 Congress Report, summary of sessions by GSK’s global medical experts in asthma and COPD, expert quotes and highlights on new respiratory data and opinion

Emerging Science

GSK is committed to generate new evidence, embracing emerging science and landmark clinical studies, to help physicians address unanswered questions in asthma and COPD

Respiratory

A comprehensive source of respiratory information and services, designed to help you support your patients.

Search Results

GlaxoSmithKline (GSK) UK healthcare professional website search results.

Relvar Ellipta

Fluticasone Furoate, Vilanterol</br> Respiratory

Incruse Ellipta

Umeclidinium <br>Respiratory</br>

Avodart

Dutasteride/Dutasteride and Tasulosim</br> Urology

Drug-Drug Interactions

Learn more about TIVICAY

Safety and Tolerability

Learn more about TIVICAY

Indication and Dosing

Learn more about TIVICAY

Tivicay

Dolutegravir </br> HIV

Clinical Data

Learn more about TIVICAY

Drug-Drug Interactions

Learn more about TRIUMEQ

DTG - Related studies

Learn more about TRIUMEQ

Triumeq

Dolutegravir/abacavir/lamivudine </br> HIV

Indication and Dosing

Learn more about TRIUMEQ

Clinical data

Learn more about TRIUMEQ

HLA-B✲5701 Screening

Learn more about TRIUMEQ

Keppra

levetiracetam</br> Neurology

Stephanie

Trelegy Ellipta is a triple therapy for appropriate patients with COPD.

Alexander

Trelegy Ellipta is a triple therapy for appropriate patients with COPD.

Trelegy

fluticasone furoate/umeclidinium/vilanterol <br> Respiratory

Exacerbations (IMPACT)

Trelegy Ellipta is a Triple Therapy indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA.

Exacerbations (FULFIL)

Trelegy Ellipta is a triple therapy for appropriate patients with COPD.

Quality of Life (FULFIL)

Trelegy Ellipta is a triple therapy for appropriate patients with COPD.

Lung Function (FULFIL)

Trelegy Ellipta is a triple therapy for appropriate patients with COPD.

FAQs

Trelegy Ellipta is a triple therapy for appropriate patients with COPD. This page provides answers to some frequently asked questions.

Nucala

Mepolizumab</br> Respiratory

Patient FAQs

Guidance for health care professionals about preparing and administering Nucala targeted add-on asthma treatment for adult patients with severe refractory eosinophilic asthma

Help for Patients

Guidance for health care professionals about preparing and administering Nucala targeted add-on asthma treatment for adult patients with severe refractory eosinophilic asthma

Dosing & Administration

Guidance for health care professionals about preparing and administering Nucala targeted add-on asthma treatment for adult patients with severe refractory eosinophilic asthma

Disease Overview

Information for healthcare professionals about the role of eosinophils in patients with severe eosinophilic asthma, identification and associated symptoms of eosinophilic asthma

Nucala

Mepolizumab <br>Respiratory</br>

Introducing Nucala

Information for healthcare professionals about prescription medicine Nucala, the first targeted anti-IL-5 add-on therapy for your adult patients with severe refractory eosinophilic asthma

Patient Identification

Information for healthcare professionals about identifying adult patients with severe refractory eosinophilic asthma who may benefit from targeted anti-IL-5 add-on treatment with Nucala

May

No results. Why not try:

  • Checking the spelling of the search term
  • Trying a different search term
  • Resetting or revising the filter settings (if you used filters to do this search)

show more